{"entity":{"type":"insider","cik":"0001763494","url":"/insider/0001763494","json_url":"/insider/0001763494.json","name":"Dube Eric M","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":45,"n_filings":30,"first":"2020-01-08","last":"2026-05-06","span_basis":"filed_date"},"name_variants":[{"name":"Dube Eric M","source":"filing","n_filings":30,"first_seen":"2020-01-08","last_seen":"2026-05-06"}],"transactions":[{"id":5747288,"accession":"0001763494-26-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001763494-26-000006","line_url":"/filing/0001763494-26-000006#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22500.0,"shares_display":"22,500","price_per_share":43.95,"price_display":"43.95","price_state":"stated","total_value":988875.0,"total_display":"988,875.00","total_whole":"988,875","shares_owned_after":432886.0,"shares_owned_after_display":"432,886","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-06","filed_date":"2026-05-06","scope":"insider"},{"id":5767499,"accession":"0001763494-26-000005","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001763494-26-000005","line_url":"/filing/0001763494-26-000005","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":64000.0,"shares_display":"64,000","price_per_share":41.0933609375,"price_display":"41.09","price_state":"stated","total_value":2629975.1,"total_display":"2,629,975.10","total_whole":"2,629,975","shares_owned_after":440071.0,"shares_owned_after_display":"440,071","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-15","filed_date":"2026-04-15","scope":"insider","n_lines":3},{"id":6026067,"accession":"0001763494-26-000004","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001763494-26-000004","line_url":"/filing/0001763494-26-000004","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60000.0,"shares_display":"60,000","price_per_share":30.930653,"price_display":"30.93","price_state":"stated","total_value":1855839.18,"total_display":"1,855,839.18","total_whole":"1,855,839","shares_owned_after":457984.0,"shares_owned_after_display":"457,984","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-04-02","scope":"insider","n_lines":2},{"id":6158952,"accession":"0001763494-26-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001763494-26-000003","line_url":"/filing/0001763494-26-000003#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60000.0,"shares_display":"60,000","price_per_share":30.0961,"price_display":"30.10","price_state":"stated","total_value":1805766.0,"total_display":"1,805,766.00","total_whole":"1,805,766","shares_owned_after":432886.0,"shares_owned_after_display":"432,886","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-20","filed_date":"2026-02-24","scope":"insider"},{"id":6158949,"accession":"0001763494-26-000002","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001763494-26-000002","line_url":"/filing/0001763494-26-000002","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100087.0,"shares_display":"100,087","price_per_share":32.275076883111694,"price_display":"32.28","price_state":"stated","total_value":3230315.62,"total_display":"3,230,315.62","total_whole":"3,230,316","shares_owned_after":466521.0,"shares_owned_after_display":"466,521","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-03","scope":"insider","n_lines":2},{"id":5886272,"accession":"0001763494-26-000001","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001763494-26-000001","line_url":"/filing/0001763494-26-000001#line-4","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51865.0,"shares_display":"51,865","price_per_share":30.097,"price_display":"30.10","price_state":"stated","total_value":1560980.905,"total_display":"1,560,980.90","total_whole":"1,560,981","shares_owned_after":419173.0,"shares_owned_after_display":"419,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-27","filed_date":"2026-01-27","scope":"insider"},{"id":5886268,"accession":"0001763494-26-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001763494-26-000001","line_url":"/filing/0001763494-26-000001#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8135.0,"shares_display":"8,135","price_per_share":30.0127,"price_display":"30.01","price_state":"stated","total_value":244153.3145,"total_display":"244,153.31","total_whole":"244,153","shares_owned_after":419173.0,"shares_owned_after_display":"419,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-23","filed_date":"2026-01-27","scope":"insider"},{"id":4777489,"accession":"0001763494-25-000005","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001763494-25-000005","line_url":"/filing/0001763494-25-000005#line-4","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27128.0,"shares_display":"27,128","price_per_share":30.1192,"price_display":"30.12","price_state":"stated","total_value":817073.6576,"total_display":"817,073.66","total_whole":"817,074","shares_owned_after":419173.0,"shares_owned_after_display":"419,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-29","filed_date":"2025-10-30","scope":"insider"},{"id":4777479,"accession":"0001763494-25-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001763494-25-000005","line_url":"/filing/0001763494-25-000005#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":92872.0,"shares_display":"92,872","price_per_share":30.379,"price_display":"30.38","price_state":"stated","total_value":2821358.488,"total_display":"2,821,358.49","total_whole":"2,821,358","shares_owned_after":419173.0,"shares_owned_after_display":"419,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-28","filed_date":"2025-10-30","scope":"insider"},{"id":4589584,"accession":"0001415889-25-012058","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-012058","line_url":"/filing/0001415889-25-012058#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18924.0,"shares_display":"18,924","price_per_share":21.05,"price_display":"21.05","price_state":"stated","total_value":398350.2,"total_display":"398,350.20","total_whole":"398,350","shares_owned_after":419173.0,"shares_owned_after_display":"419,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-05","filed_date":"2025-05-05","scope":"insider"},{"id":4145755,"accession":"0001415889-25-003820","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-003820","line_url":"/filing/0001415889-25-003820#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11375.0,"shares_display":"11,375","price_per_share":24.04,"price_display":"24.04","price_state":"stated","total_value":273455.0,"total_display":"273,455.00","total_whole":"273,455","shares_owned_after":419173.0,"shares_owned_after_display":"419,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-11","filed_date":"2025-02-12","scope":"insider"},{"id":4706456,"accession":"0001415889-25-003065","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-003065","line_url":"/filing/0001415889-25-003065#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50691.0,"shares_display":"50,691","price_per_share":20.2076,"price_display":"20.21","price_state":"stated","total_value":1024343.4516,"total_display":"1,024,343.45","total_whole":"1,024,343","shares_owned_after":430548.0,"shares_owned_after_display":"430,548","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-02-04","scope":"insider"},{"id":4706214,"accession":"0001415889-25-002006","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-002006","line_url":"/filing/0001415889-25-002006#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10736.0,"shares_display":"10,736","price_per_share":19.46,"price_display":"19.46","price_state":"stated","total_value":208922.56,"total_display":"208,922.56","total_whole":"208,923","shares_owned_after":351239.0,"shares_owned_after_display":"351,239","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-22","filed_date":"2025-01-23","scope":"insider"},{"id":2900549,"accession":"0001415889-24-023094","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-023094","line_url":"/filing/0001415889-24-023094#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21125.0,"shares_display":"21,125","price_per_share":11.52,"price_display":"11.52","price_state":"stated","total_value":243360.0,"total_display":"243,360.00","total_whole":"243,360","shares_owned_after":361975.0,"shares_owned_after_display":"361,975","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-09","filed_date":"2024-09-09","scope":"insider"},{"id":2856204,"accession":"0001415889-24-002285","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-002285","line_url":"/filing/0001415889-24-002285","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19122.0,"shares_display":"19,122","price_per_share":8.703852243489175,"price_display":"8.70","price_state":"stated","total_value":166435.0626,"total_display":"166,435.06","total_whole":"166,435","shares_owned_after":350600.0,"shares_owned_after_display":"350,600","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-01","filed_date":"2024-02-02","scope":"insider","n_lines":2},{"id":3052399,"accession":"0001415889-24-001799","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-001799","line_url":"/filing/0001415889-24-001799#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7873.0,"shares_display":"7,873","price_per_share":8.96,"price_display":"8.96","price_state":"stated","total_value":70542.08,"total_display":"70,542.08","total_whole":"70,542","shares_owned_after":234722.0,"shares_owned_after_display":"234,722","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-25","scope":"insider"},{"id":8334758,"accession":"0001209191-23-048255","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-048255","line_url":"/filing/0001209191-23-048255#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4455.0,"shares_display":"4,455","price_per_share":14.71,"price_display":"14.71","price_state":"stated","total_value":65533.05,"total_display":"65,533.05","total_whole":"65,533","shares_owned_after":242595.0,"shares_owned_after_display":"242,595","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-05","filed_date":"2023-09-05","scope":"insider"},{"id":7949000,"accession":"0001209191-23-006417","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-006417","line_url":"/filing/0001209191-23-006417#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8196.0,"shares_display":"8,196","price_per_share":22.25,"price_display":"22.25","price_state":"stated","total_value":182361.0,"total_display":"182,361.00","total_whole":"182,361","shares_owned_after":237150.0,"shares_owned_after_display":"237,150","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-01","filed_date":"2023-02-02","scope":"insider"},{"id":8151118,"accession":"0001209191-23-005034","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-005034","line_url":"/filing/0001209191-23-005034#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6442.0,"shares_display":"6,442","price_per_share":21.5,"price_display":"21.50","price_state":"stated","total_value":138503.0,"total_display":"138,503.00","total_whole":"138,503","shares_owned_after":147846.0,"shares_owned_after_display":"147,846","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-24","filed_date":"2023-01-26","scope":"insider"},{"id":8287163,"accession":"0001209191-23-002327","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002327","line_url":"/filing/0001209191-23-002327#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5625.0,"shares_display":"5,625","price_per_share":20.75,"price_display":"20.75","price_state":"stated","total_value":116718.75,"total_display":"116,718.75","total_whole":"116,719","shares_owned_after":154288.0,"shares_owned_after_display":"154,288","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-05","filed_date":"2023-01-06","scope":"insider"},{"id":6668057,"accession":"0001209191-22-008818","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-008818","line_url":"/filing/0001209191-22-008818#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4832.0,"shares_display":"4,832","price_per_share":27.84,"price_display":"27.84","price_state":"stated","total_value":134522.88,"total_display":"134,522.88","total_whole":"134,523","shares_owned_after":159913.0,"shares_owned_after_display":"159,913","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-10","filed_date":"2022-02-11","scope":"insider"},{"id":6976818,"accession":"0001209191-22-006357","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-006357","line_url":"/filing/0001209191-22-006357#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4813.0,"shares_display":"4,813","price_per_share":27.4,"price_display":"27.40","price_state":"stated","total_value":131876.2,"total_display":"131,876.20","total_whole":"131,876","shares_owned_after":164745.0,"shares_owned_after_display":"164,745","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-02-02","scope":"insider"},{"id":6242510,"accession":"0001209191-22-005078","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-005078","line_url":"/filing/0001209191-22-005078#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7873.0,"shares_display":"7,873","price_per_share":24.98,"price_display":"24.98","price_state":"stated","total_value":196667.54,"total_display":"196,667.54","total_whole":"196,668","shares_owned_after":131710.0,"shares_owned_after_display":"131,710","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-24","filed_date":"2022-01-26","scope":"insider"},{"id":6344338,"accession":"0001209191-22-002156","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-002156","line_url":"/filing/0001209191-22-002156","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":29.9495168,"price_display":"29.95","price_state":"stated","total_value":374368.96,"total_display":"374,368.96","total_whole":"374,369","shares_owned_after":141722.0,"shares_owned_after_display":"141,722","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-05","filed_date":"2022-01-06","scope":"insider","n_lines":2},{"id":6344328,"accession":"0001209191-22-002156","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-002156","line_url":"/filing/0001209191-22-002156#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4832.0,"shares_display":"4,832","price_per_share":30.43,"price_display":"30.43","price_state":"stated","total_value":147037.76,"total_display":"147,037.76","total_whole":"147,038","shares_owned_after":152083.0,"shares_owned_after_display":"152,083","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-04","filed_date":"2022-01-06","scope":"insider"},{"id":5294152,"accession":"0001209191-21-052084","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-052084","line_url":"/filing/0001209191-21-052084#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7836.0,"shares_display":"7,836","price_per_share":17.1187,"price_display":"17.12","price_state":"stated","total_value":134142.1332,"total_display":"134,142.13","total_whole":"134,142","shares_owned_after":156915.0,"shares_owned_after_display":"156,915","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-17","filed_date":"2021-08-17","scope":"insider"},{"id":5476525,"accession":"0001209191-21-037615","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-037615","line_url":"/filing/0001209191-21-037615#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4780.0,"shares_display":"4,780","price_per_share":14.35,"price_display":"14.35","price_state":"stated","total_value":68593.0,"total_display":"68,593.00","total_whole":"68,593","shares_owned_after":147251.0,"shares_owned_after_display":"147,251","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-02","filed_date":"2021-06-03","scope":"insider"},{"id":5476521,"accession":"0001209191-21-037615","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-037615","line_url":"/filing/0001209191-21-037615#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4782.0,"shares_display":"4,782","price_per_share":14.89,"price_display":"14.89","price_state":"stated","total_value":71203.98,"total_display":"71,203.98","total_whole":"71,204","shares_owned_after":152031.0,"shares_owned_after_display":"152,031","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-01","filed_date":"2021-06-03","scope":"insider"},{"id":4773218,"accession":"0001209191-21-008795","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-008795","line_url":"/filing/0001209191-21-008795#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4813.0,"shares_display":"4,813","price_per_share":31.58,"price_display":"31.58","price_state":"stated","total_value":151994.54,"total_display":"151,994.54","total_whole":"151,995","shares_owned_after":156813.0,"shares_owned_after_display":"156,813","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-09","scope":"insider"},{"id":4773214,"accession":"0001209191-21-008795","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-008795","line_url":"/filing/0001209191-21-008795#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4813.0,"shares_display":"4,813","price_per_share":31.41,"price_display":"31.41","price_state":"stated","total_value":151176.33,"total_display":"151,176.33","total_whole":"151,176","shares_owned_after":161626.0,"shares_owned_after_display":"161,626","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-05","filed_date":"2021-02-09","scope":"insider"},{"id":4982360,"accession":"0001209191-21-007631","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-007631","line_url":"/filing/0001209191-21-007631#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2406.0,"shares_display":"2,406","price_per_share":28.91,"price_display":"28.91","price_state":"stated","total_value":69557.46,"total_display":"69,557.46","total_whole":"69,557","shares_owned_after":148939.0,"shares_owned_after_display":"148,939","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-03","filed_date":"2021-02-03","scope":"insider"},{"id":4772838,"accession":"0001209191-21-007025","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-007025","line_url":"/filing/0001209191-21-007025","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8734.0,"shares_display":"8,734","price_per_share":29.913753423402795,"price_display":"29.91","price_state":"stated","total_value":261266.7224,"total_display":"261,266.72","total_whole":"261,267","shares_owned_after":153751.0,"shares_owned_after_display":"153,751","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-02","filed_date":"2021-02-02","scope":"insider","n_lines":2},{"id":5543880,"accession":"0001209191-21-002592","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-002592","line_url":"/filing/0001209191-21-002592#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3438.0,"shares_display":"3,438","price_per_share":27.01,"price_display":"27.01","price_state":"stated","total_value":92860.38,"total_display":"92,860.38","total_whole":"92,860","shares_owned_after":87819.0,"shares_owned_after_display":"87,819","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-06","filed_date":"2021-01-07","scope":"insider"},{"id":5543878,"accession":"0001209191-21-002592","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-002592","line_url":"/filing/0001209191-21-002592#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3438.0,"shares_display":"3,438","price_per_share":26.65,"price_display":"26.65","price_state":"stated","total_value":91622.7,"total_display":"91,622.70","total_whole":"91,623","shares_owned_after":91257.0,"shares_owned_after_display":"91,257","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-05","filed_date":"2021-01-07","scope":"insider"},{"id":2657793,"accession":"0001209191-20-051611","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-051611","line_url":"/filing/0001209191-20-051611","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10805.0,"shares_display":"10,805","price_per_share":19.279904951411385,"price_display":"19.28","price_state":"stated","total_value":208319.373,"total_display":"208,319.37","total_whole":"208,319","shares_owned_after":96260.0,"shares_owned_after_display":"96,260","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-21","filed_date":"2020-09-22","scope":"insider","n_lines":2},{"id":2356356,"accession":"0001209191-20-002631","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-002631","line_url":"/filing/0001209191-20-002631#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":15.14,"price_display":"15.14","price_state":"stated","total_value":56775.0,"total_display":"56,775.00","total_whole":"56,775","shares_owned_after":42500.0,"shares_owned_after_display":"42,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-08","filed_date":"2020-01-08","scope":"insider"},{"id":2356352,"accession":"0001209191-20-002631","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-002631","line_url":"/filing/0001209191-20-002631#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001763494","owner_name":"Dube Eric M","owner_display_name":"Dube Eric M","owner_url":"/insider/0001763494","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":13.94,"price_display":"13.94","price_state":"stated","total_value":52275.0,"total_display":"52,275.00","total_whole":"52,275","shares_owned_after":46250.0,"shares_owned_after_display":"46,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-07","filed_date":"2020-01-08","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":45,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":45,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":45},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001438533","name":"Travere Therapeutics, Inc.","url":"/issuer/0001438533","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","n_filings":30,"first_seen":"2020-01-08","last_seen":"2026-05-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001763494","retrieved_at":"2026-08-23T06:19:23+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}